From Mind To Market - Boehringer Ingelheim

More documents

Recommendations

Info

24 Work with us Companies choose contract development and manufacturing because it offers an attractive solution to bring a biopharmaceutical to market as efficiently as possible, without prohibitive financial risk. Companies choose to work with us in particular, because our experience and resources guarantee competitive manufacturing processes and timely market supply. They find that we are not only innovative in the technical sense, but that our team brings a creative approach to our partnerships. The team approach Inter-company teams run all our partnership projects. These experts agree on the timelines and interim objectives required in developing a manufacturing process with optimum efficiency, safety and cost-effectiveness. Designated project managers from each side coordinate the process, meeting regularly with team members and, when not meeting in person, keeping in touch by telephone and videoconferences. A project group will typically contain senior scientists from process science, fermentation and downstream processing, fill & finish, quality control and quality assurance. Naturally, everyone assigned to a project team at <strong>Boehringer</strong> <strong>Ingelheim</strong> has extensive experience in biopharmaceutical development, manufacturing, quality and regulatory issues. As a matter of company policy, our employees follow an intensive cGMP education programme. In addition, where new skills and techniques are involved, we provide project-specific training.
Finding the best-fit strategy for your product Projects, where the expectation of success in clinical trials is high, can be developed with a time to market strategy. In this approach, key phases are conducted in parallel, allowing the shortest possible timeline and the earliest possible return on investment. For highly innovative projects, carrying a certain development risk during pre-clinical and clinical evaluation, we are open to a step-by-step approach. However, this strategy necessarily requires a longer development phase for the manufacturing process and consequently delays entry to the market and return on investment. 25
Page 1 and 2: Value through Innovation From Mind
Page 3 and 4: Company profile The Boehringer Inge
Page 5 and 6: Biotechnology pioneers Boehringer I
Page 7 and 8: The key to success For any biopharm
Page 9 and 10: Best fit for your strategic plan Al
Page 11 and 12: Centers of Excellence The global in
Page 13 and 14: Microbial fermentation technology B
Page 15 and 16: Mammalian cell culture technology T
Page 18 and 19: 18 We have the expertise Value and
Page 20 and 21: 20 We have the track record Ongoing
Page 22 and 23: 22 We have the track record Many or
Page 26 and 27: 26 Time to market Tailor-made servi
Page 28: Contact us This brochure is an intr

From Mind To Market - Boehringer Ingelheim

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?